Clinical trials: Patients With Advanced Solid Tumors
Solid Tumors, Lymphomas
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD).
- Trial name
- NCT02661542
- Testing
- FF-10502-01
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer, Advanced Solid Tumor
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2…
- Trial name
- NCT06299124
- Testing
- RGT-419B
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Regor Pharmaceuticals Inc.
Malignant Neoplasms
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
- Trial name
- NCT04343859
- Testing
- IMMH-010
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Study of CPI-200 in Patients With Advanced Tumors
This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3…
- Trial name
- NCT03953742
- Testing
- CPI-200
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Advanced Solid Tumor
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors.
- Trial name
- NCT06258408
- Testing
- BB102 tablet
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Broadenbio Ltd., Co.
Cancer, Solid Tumor
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
This will be a multi-center, open-label, single-arm, prospective study, in which up to 18 adult patients requiring radiotherapy for metastatic disease or for an inoperable primary tumor with no definitive curative treatment…
- Conditions
- Cancer, Solid Tumor, Metastatic Disease
- Trial name
- NCT03823989
- Testing
- Promitil, EBR
- Where
- 3 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Neoplasms
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
This study will determine the maximum tolerated dose, and assess the safety, tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors.
- Trial name
- NCT00493155
- Testing
- RG1530
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
Advanced or Metastatic Solid Tumors
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with…
- Trial name
- NCT07702955
- Testing
- KGX105 injection
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Advanced Cancer, Advanced Solid Tumor
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05525455
- Testing
- TT-816, A PD-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Teon Therapeutics, Inc.
Solid Tumor, Non-Hodgkin Lymphoma
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma.
- Trial name
- NCT03802955
- Testing
- ADG106
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Adagene (Suzhou) Limited
Endometrial Adenocarcinomas, Neuroendocrine Tumors
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose…
- Conditions
- Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
- Trial name
- NCT01970540
- Testing
- lurbinectedin (PM01183), Doxorubicin
- Where
- 7 sites in Spain, United Kingdom
- Volunteers
- 122 people
- Sponsor
- PharmaMar
Solid Cancers, Non-Hodgkin's Lymphoma
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages.
- Trial name
- NCT01296555
- Testing
- Fulvestrant, GDC-0032, Letrozole
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 674 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors, Metastatic Colon Cancer
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.
- Conditions
- Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03251378
- Testing
- Fruquintinib (HMPL-013)
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- Hutchison Medipharma Limited
Tumors
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.
- Trial name
- NCT00960258
- Testing
- Regorafenib (BAY73-4506)
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Bayer
Advanced Solid Tumors, Lymphoma
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT01898078
- Testing
- Alisertib
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumor
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
- Trial name
- NCT05429398
- Testing
- Linperlisib Tablet
- Volunteers
- 118 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.